Cimaher Dosage/Direction for Use

Advanced Head and Neck Cancers and Nasopharyngeal Carcinoma: The recommended dose Cimaher for head and neck cancer is 200 mg once a week for 6 weeks in combination with radiotherapy and/or chemotherapy. The recommended dose Cimaher for nasopharyngeal carcinoma is 200 mg once a week for 8 weeks in combinations with radiation.
Subsequently, it will be administered a dose of 200 mg Cimaher every 15 days (maintenance dose) until the patient's general condition permits.
Glioma: The recommended dose Cimaher for glioma in adults is 200 mg weekly in combination with conventional radiation treatment. Subsequently, it will be administered a dose of 200 mg Cimaher every 15 days (maintenance dose) until the patient's general condition permits.
Dosage for glioma in children & adolescents: monotherapy in two consecutive phases, induction phase and consolidation phase. During induction phase, Cimaher is given at 150 mg/m² BSA weekly for 6 weeks. After induction, patient without progressive disease upon 8^th week evaluation will be treated in the consolidation phase where Cimaher is given at 150 mg/m² BSA every 3 weeks until disease progression.
Inoperable Esophageal Malignancy with Epithelial Origin: The recommended dose Cimaher for esophageal cancer is 200 mg administered once a week during 6 weeks concomitantly with standard radiotherapy and/or chemotherapy.
Administration: The recommended dosage of Cimaher (Nimotuzumab or h-R3) in each indication is administered as continuous intravenous (IV) infusions combination with a standard radiotherapy and/or chemotherapy. Nimotuzumab is diluted in 250 ml of sodium chloride 0.9% solution and administered intravenously within 60 minutes for adult patients and 30 minutes for pediatric/adolescent patients. Pretreatment with diphenhydramine is recommended to minimize possible infusion reaction especially for patients having history of hypersensitivity reaction to any monoclonal antibody or any medicinal products.